Open AccessA 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis
Author(s) -
Kristian Reich,
Richard Langley,
Kim Papp,
JeanPaul Ortonne,
Kristina Unnebrink,
Martin Kaul,
Joaquin Valdes
Publication year - 2011
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1010858
Subject(s) - medicine , psoriasis , methotrexate , psoriasis area and severity index , gastroenterology , surgery , dermatology
Briakinumab is a monoclonal antibody against the p40 molecule shared by interleukin-12 and interleukin-23, which is overexpressed in psoriatic skin lesions. We assessed the efficacy and safety of briakinumab as compared with methotrexate in patients with psoriasis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom